Gait

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

Retrieved on: 
Monday, February 19, 2024

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.

Key Points: 
  • A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
  • This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
  • Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
  • Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.

S.BIOMEDICS completes brain transplant of hESC-derived dopaminergic progenitors (TED-A9) for Phase 1/2a study in patients with Parkinson’s disease

Retrieved on: 
Thursday, February 29, 2024

S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.

Key Points: 
  • S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.
  • The primary objective of the Phase 1/2a trial is to assess the safety and exploratory efficacy of TED-A9 transplantation for two years post-transplant.
  • “We have developed a fundamental therapeutic mechanism that directly replaces dopaminergic neurons lost in patients with Parkinson's disease.
  • TED-A9 could represent a fundamental treatment that surpasses current therapies, which only temporarily alleviate the symptoms of Parkinson’s disease,” he added.

Cutting Edge Data Reveals Improved Sensitivity of PD Motor Progression with Wearable Sensors, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 21, 2024

TORONTO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- The development and deployment of disease-modifying interventions for Parkinson's disease (PD) have been limited due to a lack of objective, accurate and reliable measures of progression. As such, the adoption of digital technologies has increased in recent years with the intent to overcome the poor sensitivity of conventional rating scales currently used as the gold standard in clinical trials. However, natural history studies incorporating digital motor endpoints in PD are sparse. Excitingly, data recently published from key longitudinal studies reveal cutting-edge evidence demonstrating that digital endpoints of motor progression are more sensitive than conventional clinical scales.

Key Points: 
  • The featured speakers will discuss how (by capturing a composite score of digital measures of bradykinesia with wearable sensors) a better signal of disease progression can be obtained compared to independent measurements.
  • Attendees will gain insights into the future directions of wearable sensors and digital motor endpoints in clinical trials to monitor the progression of neurodegenerative diseases.
  • TORONTO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- The development and deployment of disease-modifying interventions for Parkinson's disease (PD) have been limited due to a lack of objective, accurate and reliable measures of progression.
  • Excitingly, data recently published from key longitudinal studies reveal cutting-edge evidence demonstrating that digital endpoints of motor progression are more sensitive than conventional clinical scales.

National Experts in Psychology, Addiction Counseling, and Clinical Services Join Kyros' Inaugural Independent Clinical Advisory Board

Retrieved on: 
Tuesday, February 20, 2024

MINNEAPOLIS, Feb. 20, 2024 /PRNewswire/ -- In a significant move to strengthen its commitment to addressing substance use disorders and enhancing community recovery efforts, Kyros is excited to announce the establishment of its Independent Clinical Advisory Board and the following appointments:

Key Points: 
  • The Clinical Advisory Board's mission is to independently advise Kyros leadership on improving care and outcomes for individuals with substance use disorders.
  • It does this by providing evidence-based recommendations, promoting collaboration among stakeholders, and driving continuous improvement in recovery care services.
  • Professor Helwig is the author of 10 open-source statistical software packages, which have amassed over 1,000,000 downloads in recent years.
  • Their profound expertise will play a pivotal role in tackling urgent issues such as the opioid epidemic, dual diagnosis, and the need for comprehensive recovery support services."

Wandercraft's self-balancing exoskeleton receives second FDA clearance in less than a year, now indicated for rehabilitation in patients with spinal cord injury

Retrieved on: 
Tuesday, February 13, 2024

NEW YORK – 13 February 2024 -- Wandercraft, the developer of the world's first self-balancing robotic exoskeleton that enables people with limited mobility to stand up and walk again, announced today that it has received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries (SCI) at levels T5 to L5.

Key Points: 
  • Matthieu Masselin, CEO of Wandercraft, commented, “Today’s FDA clearance for individuals with spinal cord injuries speaks volumes about the amazing possibilities for Atalante X.
  • The unique ankle motion, combined with intelligent self-balancing technology, means that patients can experience the benefits of once-again walking in a rehabilitation setting.
  • “At Kessler, we are committed to researching promising advances in robotics technology that offer innovative approaches to improving functional recovery.
  • Evaluation of safety and performance of the self balancing walking system Atalante in patients with complete motor spinal cord injury.

MedRhythms Announces Key Publications Confirming Efficacy, Safety, and Usability of InTandem™ for Chronic Stroke Walking Impairment

Retrieved on: 
Thursday, February 8, 2024

Historically, there has been a key care gap in the availability of efficacious walking rehabilitation interventions for the chronic phase of stroke recovery, typically defined as six or more months after the initial stroke.

Key Points: 
  • Historically, there has been a key care gap in the availability of efficacious walking rehabilitation interventions for the chronic phase of stroke recovery, typically defined as six or more months after the initial stroke.
  • There are few interventions that can help people with chronic stroke gait impairment improve both their gait speed and quality.
  • In the randomized controlled trial, study participants with chronic stroke were randomly assigned to InTandem or an active control group.
  • These results confirm InTandem's safety and efficacy for home use by patients living with gait impairment in the chronic stroke recovery phase.

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Retrieved on: 
Tuesday, February 6, 2024

NEWTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors. Helius’ registrational program includes two controlled studies. The clinical program will leverage a randomized, controlled, double blinded investigator-initiated trial (“IIT”), led by Dr. Steven Kautz at the Medical University of South Carolina (“MUSC”) and a Company-sponsored study to enroll approximately 100 subjects. Dr. Kautz’s IIT began enrollment of 60 participants in September 2023 with the collaboration of Dr. Mark Bowden at Brooks Rehabilitation as a second site.

Key Points: 
  • “Vetting the registrational program and design of our clinical studies with the FDA is an important milestone for Helius and meeting the agency’s expectations will give us the most efficient path to delivering PoNS Therapy to stroke patients,” said Dr. Antonella Favit-Van Pelt, Helius’ Chief Medical Officer.
  • Across all stroke patients in the database, 69.2% of patients experienced at least a 5-point FGA improvement, which is larger than the 4.2-point minimal detectable change usually seen in stroke patients.
  • “One of our chief objectives is to optimize access to PoNS Therapy for stroke patients suffering from gait and balance deficit in North America.
  • PoNS received breakthrough designations in both multiple sclerosis and stroke in the United States, potentially benefiting, with a new indication, an estimated 90% of stroke patients who are covered by Medicare.

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Retrieved on: 
Monday, February 5, 2024

CSM attendees can register for the after-hours event at booth 7074 or online at https://forms.gle/FEqwwRZpJj38aJRW9 .

Key Points: 
  • CSM attendees can register for the after-hours event at booth 7074 or online at https://forms.gle/FEqwwRZpJj38aJRW9 .
  • Helius’ appearance at the conference follows the first full year PoNS was available to MS patients in the United States, during which Helius’ engagement with physical therapists grew remarkably.
  • These topics will carry over to the after-hours event, held from 5-6:30 p.m. on February 16 at booth 7074.
  • “PoNS Therapy gives physical therapists a powerful new tool to counter some of the life-changing effects of MS, and we look forward to speaking with physical therapists about PoNS and highlighting its therapeutic potential.”

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™

Retrieved on: 
Tuesday, January 23, 2024

As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.

Key Points: 
  • As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - patients’ and caregivers’ assessments.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO)- baseline clinical data.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - evaluation of different assessments.

PIH Health One of the First in LA to Offer Persona IQ®, the World's First and Only Smart Knee Implant for Total Knee Replacement Surgery

Retrieved on: 
Thursday, January 25, 2024

WHITTIER, Calif., Jan. 25, 2024 /PRNewswire/ -- PIH Health is now offering Persona IQ®, the world's first and only smart knee implant granted "De Novo" status (assurance of safety and effectiveness) by the U.S. Food and Drug Administration for total knee replacement surgery.

Key Points: 
  • WHITTIER, Calif., Jan. 25, 2024 /PRNewswire/ -- PIH Health is now offering Persona IQ®, the world's first and only smart knee implant granted "De Novo" status (assurance of safety and effectiveness) by the U.S. Food and Drug Administration for total knee replacement surgery.
  • Persona IQ combines the proven and trusted knee implant, Persona ® The Personalized Knee ® , with implantable sensor technology that measures range of motion, step count, walking speed and other gait metrics.
  • "We're delighted to be one of the first in Los Angeles to offer the Persona IQ smart knee as an option to our patients and those considering knee replacement surgery at PIH Health," said Andrew Luu MD, PIH Health orthopedic surgeon.
  • Persona IQ will work together with mymobility®, a remote care management platform that monitors pre- and post-operative mobility metrics.